Methodological issues in primary prevention trials for neurodegenerative dementia

Sandrine Andrieu, Nicola Coley, Paul Aisen, Maria C. Carrillo, Steven Dekosky, Jane Durga, Howard Fillit, Giovanni B. Frisoni, Lutz Froelich, Serge Gauthier, Roy Jones, Linus Jönsson, Zaven Khachaturian, John C. Morris, Jean Marc Orgogozo, Pierre Jean Ousset, Philippe Robert, Eric Salmon, Cristina Sampaio, Frans VerheyGordon Wilcock, Bruno Vellas

Research output: Contribution to journalArticle

Abstract

The prevention of neurodegenerative dementias, such as Alzheimer's disease, is a public health priority. Due to the large numbers of affected patients, even interventions bringing about a relatively small delay in disease onset could have large public health effects. Randomized controlled trials (RCTs) are required to demonstrate the effectiveness of preventive interventions, but such trials raise specific methodological questions because they are new in the field of neurodegenerative diseases, and require large numbers of elderly subjects and lengthy follow-up periods. We performed a literature search to identify primary prevention RCTs for neurodegenerative dementia. The methodology of the trials was summarized and discussed during two expert meetings. Overall, 39 trials were identified that assessed dementia incidence or cognitive decline as a primary or secondary study outcome. Age was the most common selection criteria for target populations. Follow-up periods ranged from one month to nine years and were longest in studies measuring dementia incidence as an outcome. Results of RCTs have so far been generally negative and conflicting with those of observational studies, perhaps due to methodological issues. Future trials must therefore carefully consider the target population, outcomes and duration of follow-up to be used, and should assess the problem of attrition.

Original languageEnglish (US)
Pages (from-to)235-270
Number of pages36
JournalJournal of Alzheimer's Disease
Volume16
Issue number2
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Primary Prevention
Dementia
Randomized Controlled Trials
Health Services Needs and Demand
Public Health
Health Priorities
Incidence
Neurodegenerative Diseases
Patient Selection
Observational Studies
Alzheimer Disease
Outcome Assessment (Health Care)

Keywords

  • Alzheimer's disease
  • Clinical trials
  • Clinical trials methodology
  • Cognitive aging
  • Cognitive decline
  • Dementia
  • Prevention trials
  • Study design

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Cite this

Andrieu, S., Coley, N., Aisen, P., Carrillo, M. C., Dekosky, S., Durga, J., ... Vellas, B. (2009). Methodological issues in primary prevention trials for neurodegenerative dementia. Journal of Alzheimer's Disease, 16(2), 235-270. https://doi.org/10.3233/JAD-2009-0971

Methodological issues in primary prevention trials for neurodegenerative dementia. / Andrieu, Sandrine; Coley, Nicola; Aisen, Paul; Carrillo, Maria C.; Dekosky, Steven; Durga, Jane; Fillit, Howard; Frisoni, Giovanni B.; Froelich, Lutz; Gauthier, Serge; Jones, Roy; Jönsson, Linus; Khachaturian, Zaven; Morris, John C.; Orgogozo, Jean Marc; Ousset, Pierre Jean; Robert, Philippe; Salmon, Eric; Sampaio, Cristina; Verhey, Frans; Wilcock, Gordon; Vellas, Bruno.

In: Journal of Alzheimer's Disease, Vol. 16, No. 2, 2009, p. 235-270.

Research output: Contribution to journalArticle

Andrieu, S, Coley, N, Aisen, P, Carrillo, MC, Dekosky, S, Durga, J, Fillit, H, Frisoni, GB, Froelich, L, Gauthier, S, Jones, R, Jönsson, L, Khachaturian, Z, Morris, JC, Orgogozo, JM, Ousset, PJ, Robert, P, Salmon, E, Sampaio, C, Verhey, F, Wilcock, G & Vellas, B 2009, 'Methodological issues in primary prevention trials for neurodegenerative dementia', Journal of Alzheimer's Disease, vol. 16, no. 2, pp. 235-270. https://doi.org/10.3233/JAD-2009-0971
Andrieu, Sandrine ; Coley, Nicola ; Aisen, Paul ; Carrillo, Maria C. ; Dekosky, Steven ; Durga, Jane ; Fillit, Howard ; Frisoni, Giovanni B. ; Froelich, Lutz ; Gauthier, Serge ; Jones, Roy ; Jönsson, Linus ; Khachaturian, Zaven ; Morris, John C. ; Orgogozo, Jean Marc ; Ousset, Pierre Jean ; Robert, Philippe ; Salmon, Eric ; Sampaio, Cristina ; Verhey, Frans ; Wilcock, Gordon ; Vellas, Bruno. / Methodological issues in primary prevention trials for neurodegenerative dementia. In: Journal of Alzheimer's Disease. 2009 ; Vol. 16, No. 2. pp. 235-270.
@article{54cf45257be74285a0d1e4e191fd42ff,
title = "Methodological issues in primary prevention trials for neurodegenerative dementia",
abstract = "The prevention of neurodegenerative dementias, such as Alzheimer's disease, is a public health priority. Due to the large numbers of affected patients, even interventions bringing about a relatively small delay in disease onset could have large public health effects. Randomized controlled trials (RCTs) are required to demonstrate the effectiveness of preventive interventions, but such trials raise specific methodological questions because they are new in the field of neurodegenerative diseases, and require large numbers of elderly subjects and lengthy follow-up periods. We performed a literature search to identify primary prevention RCTs for neurodegenerative dementia. The methodology of the trials was summarized and discussed during two expert meetings. Overall, 39 trials were identified that assessed dementia incidence or cognitive decline as a primary or secondary study outcome. Age was the most common selection criteria for target populations. Follow-up periods ranged from one month to nine years and were longest in studies measuring dementia incidence as an outcome. Results of RCTs have so far been generally negative and conflicting with those of observational studies, perhaps due to methodological issues. Future trials must therefore carefully consider the target population, outcomes and duration of follow-up to be used, and should assess the problem of attrition.",
keywords = "Alzheimer's disease, Clinical trials, Clinical trials methodology, Cognitive aging, Cognitive decline, Dementia, Prevention trials, Study design",
author = "Sandrine Andrieu and Nicola Coley and Paul Aisen and Carrillo, {Maria C.} and Steven Dekosky and Jane Durga and Howard Fillit and Frisoni, {Giovanni B.} and Lutz Froelich and Serge Gauthier and Roy Jones and Linus J{\"o}nsson and Zaven Khachaturian and Morris, {John C.} and Orgogozo, {Jean Marc} and Ousset, {Pierre Jean} and Philippe Robert and Eric Salmon and Cristina Sampaio and Frans Verhey and Gordon Wilcock and Bruno Vellas",
year = "2009",
doi = "10.3233/JAD-2009-0971",
language = "English (US)",
volume = "16",
pages = "235--270",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "2",

}

TY - JOUR

T1 - Methodological issues in primary prevention trials for neurodegenerative dementia

AU - Andrieu, Sandrine

AU - Coley, Nicola

AU - Aisen, Paul

AU - Carrillo, Maria C.

AU - Dekosky, Steven

AU - Durga, Jane

AU - Fillit, Howard

AU - Frisoni, Giovanni B.

AU - Froelich, Lutz

AU - Gauthier, Serge

AU - Jones, Roy

AU - Jönsson, Linus

AU - Khachaturian, Zaven

AU - Morris, John C.

AU - Orgogozo, Jean Marc

AU - Ousset, Pierre Jean

AU - Robert, Philippe

AU - Salmon, Eric

AU - Sampaio, Cristina

AU - Verhey, Frans

AU - Wilcock, Gordon

AU - Vellas, Bruno

PY - 2009

Y1 - 2009

N2 - The prevention of neurodegenerative dementias, such as Alzheimer's disease, is a public health priority. Due to the large numbers of affected patients, even interventions bringing about a relatively small delay in disease onset could have large public health effects. Randomized controlled trials (RCTs) are required to demonstrate the effectiveness of preventive interventions, but such trials raise specific methodological questions because they are new in the field of neurodegenerative diseases, and require large numbers of elderly subjects and lengthy follow-up periods. We performed a literature search to identify primary prevention RCTs for neurodegenerative dementia. The methodology of the trials was summarized and discussed during two expert meetings. Overall, 39 trials were identified that assessed dementia incidence or cognitive decline as a primary or secondary study outcome. Age was the most common selection criteria for target populations. Follow-up periods ranged from one month to nine years and were longest in studies measuring dementia incidence as an outcome. Results of RCTs have so far been generally negative and conflicting with those of observational studies, perhaps due to methodological issues. Future trials must therefore carefully consider the target population, outcomes and duration of follow-up to be used, and should assess the problem of attrition.

AB - The prevention of neurodegenerative dementias, such as Alzheimer's disease, is a public health priority. Due to the large numbers of affected patients, even interventions bringing about a relatively small delay in disease onset could have large public health effects. Randomized controlled trials (RCTs) are required to demonstrate the effectiveness of preventive interventions, but such trials raise specific methodological questions because they are new in the field of neurodegenerative diseases, and require large numbers of elderly subjects and lengthy follow-up periods. We performed a literature search to identify primary prevention RCTs for neurodegenerative dementia. The methodology of the trials was summarized and discussed during two expert meetings. Overall, 39 trials were identified that assessed dementia incidence or cognitive decline as a primary or secondary study outcome. Age was the most common selection criteria for target populations. Follow-up periods ranged from one month to nine years and were longest in studies measuring dementia incidence as an outcome. Results of RCTs have so far been generally negative and conflicting with those of observational studies, perhaps due to methodological issues. Future trials must therefore carefully consider the target population, outcomes and duration of follow-up to be used, and should assess the problem of attrition.

KW - Alzheimer's disease

KW - Clinical trials

KW - Clinical trials methodology

KW - Cognitive aging

KW - Cognitive decline

KW - Dementia

KW - Prevention trials

KW - Study design

UR - http://www.scopus.com/inward/record.url?scp=60349128705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60349128705&partnerID=8YFLogxK

U2 - 10.3233/JAD-2009-0971

DO - 10.3233/JAD-2009-0971

M3 - Article

C2 - 19221415

AN - SCOPUS:60349128705

VL - 16

SP - 235

EP - 270

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 2

ER -